Testing ARNI in people with implanted LVAD devices
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a durable LVAD (a long-term heart pump implanted)
- Your heart failure symptoms are NYHA class II, III, or IV
- Your heart pumping strength (LVEF) is under 40%
- You can and agree to sign informed consent
- You can follow the study rules and visit schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a treatment called SCD is safe and workable in people who have worsening heart failure along with kidney problems, and who are waiting to get an LVAD (a mechanical heart pump). It is mainly a feasibility study, meaning the researchers want to see if this approach can be used in real hospital care and monitor effects on key health measures.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
This trial studies whether sacubitril-valsartan works better than enalapril to improve heart healing after a specific type of heart attack. It aims to see if the heart’s shape and pumping recover more effectively.
This study tests a medication (sacubitril/valsartan) to reduce scarring in the heart muscle for people with a type of heart failure where the heart pumps well but is stiff. The goal is to see if it can improve heart function and symptoms.
This test looks at sacubitril/valsartan — a heart failure pill — in people who have a type of amyloidosis that affects the heart (called ATTR amyloidosis) and who also have a heart that pumps weakly (ejection fraction 40% or less). The goal is to see if it helps heart function and daily life.
Hear when a new Stage D Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.